|
Study
|
Athanassa [44] (n = 20)a
|
Boisson [45] (n = 12)a
|
Bihan [46] (n = 1)b
|
Lu [6] (n = 16)b
|
|---|
|
Nebulized dose
|
1 MIU
|
2 MIU
|
4 MIU
|
5 MIU
|
|
Nebulizer
|
Vibrating mesh nebulizer, continuous delivery, optimized conditions
|
|
Colistin assay
|
HPLC
|
LC–MS/MS
|
LC–MS/MS
|
HPLC
|
|
VAP/VAT
|
VAT
|
VAP
|
VAP
|
VAP
|
|
Lung ELFmax (mg/L)
|
6.73 (4.8–10.1)
|
1137
|
NA
|
NA
|
|
Lung ELFmin (mg/L)
|
2.0 (1.0–3.8)
|
9.53
|
NA
|
NA
|
|
Plasma Cmax (mg/L)
|
1.6 (1.5–1.9)
|
0.73
|
2.9
|
2.2 ± 1.3
|
|
Plasma Cmin (mg/L)
|
0.3 (0.3–0.5)
|
0.15
|
2.4
|
1.4 ± 0.9
|
- Data are presented as mean ± SD, medians (25–75% interquartile) or maximum and minimum values
-
HPLC High-performance liquid chromatography, VAP ventilator-associated pneumonia; VAT ventilator-associated tracheobronchitis, ELF epithelial lining fluid, LC–MS/MS liquid chromatography–tandem mass spectrometry, Cmax maximum plasma concentration, Cmin minimum plasma concentration
-
a Blood sampled after the first dose; b blood sample performed at steady-state
